1. SAFETY AND EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN OLDER PATIENTS: RESULTS FROM THE US LYMPHOMA CAR‐T CONSORTIUM. (12th June 2019) Authors: Sano, D.; Lekakis, L.; Feng, L.; Nastoupil, L.J.; Jain, M.D.; Spiegel, J.Y.; Dahiya, S.; Lin, Y.; Ghobadi, A.; Lunning, M.; Hill, B.T.; Reagan, P.; Oluwole, O.; McGuirk, J.; Sehgal, A.; Deol, A.; Charalambos, A.; Goy, A.H.; Munoz, J.; Cashen, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. HIGH‐RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA ARE NOT ENROLLED ON CLINICAL TRIALS. (June 2017) Authors: Reagan, P.; Loh, K.P.; Baran, A.; Hu, J.; Casulo, C.; Barr, P.M.; Friedberg, J.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY. (23rd June 2022) Authors: Sehgal, A.; Hoda, D.; Riedell, P. A.; Ghosh, N.; Hamadani, M.; Hildebrandt, G. C.; Godwin, J. E.; Reagan, P.; Wagner-Johnston, N.; Essell, J.; Nath, R.; Solomon, S. R.; Champion, R.; Licitra, E.; Fanning, S.; Gupta, N.; Dubowy, R.; D'Andrea, A.; Wang, L.; Gordon, L. I. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE‐ADJUSTED R‐EPOCH THERAPY FOR NON‐HODGKIN LYMPHOMA. (June 2017) Authors: Reagan, P.; David, R.; Baran, A.; Kelly, J.; Loh, K.; Casulo, C.; Barr, P.; Friedberg, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1. (June 2017) Authors: Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.; Siddiqi, T.; Lin, Y.; Timmerman, J.; Reagan, P.; Navale, L.; Jiang, Y.; Aycock, J.; Elias, M.; Wiezorek, J.; Go, W.Y. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗